Amgen 🧪🔬🧬 (@Amgen) header
Amgen 🧪🔬🧬 (@Amgen) profile picture

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases. 🔗 Guidelines: https://teapawt.net/t.co/IROHJVvFrV

Thousand Oaks, CA, USA
Joined April 2009
Photo by Amgen 🧪🔬🧬 (@Amgen)Photo by Amgen 🧪🔬🧬 (@Amgen)Photo by Amgen 🧪🔬🧬 (@Amgen)Photo by Amgen 🧪🔬🧬 (@Amgen)Photo by Amgen 🧪🔬🧬 (@Amgen)Photo by Amgen 🧪🔬🧬 (@Amgen)Photo by Amgen 🧪🔬🧬 (@Amgen)Photo by Amgen 🧪🔬🧬 (@Amgen)Photo by Amgen 🧪🔬🧬 (@Amgen)Photo by Amgen 🧪🔬🧬 (@Amgen)
In her latest blog, Susan Sweeney, Executive Vice President, Obesity and Related Conditions, explores the idea that obesity treatment is not simply about helping patients get started. It’s about helping them stay on the path to meaningful, long-term progress. Read more: amgen.ly/48ti6TW
1
3
10
1,205
No two obesity journeys look the same, which is why real progress in obesity care starts with listening. At #HLTHUSA, we’re putting that into practice. Watch Amy share her experience and learn why continued dialogue and understanding matter. 🔗 amgen.ly/3Xrlj3N
1
1
5
1,034
At @ACRheum’s #ACR26, researchers, clinicians and community voices surfaced unanswered questions in rare autoimmune and inflammatory diseases. Byeong Yoon explains how those exchanges can guide future research. ▶️
1
2
8
1,031
As we head into #HLTHUSA and #ObesityWeek, one thing is clear: the future of obesity care will be shaped by the conversations we have and actions we take together. By bringing together diverse voices, these meetings create opportunities to address the significant burdens that continue to impact millions of people living with obesity.
3
6
865
#SjogrensDisease news: Amgen presented late-breaking Phase 3 results at #ACR26. The study showed improvements in systemic disease activity and symptoms. 🔗 amgen.ly/4BWqWqw $AMGN
1
7
19
1,533
At AHA #ScientificSessions26, Amgen presented data highlighting the cost effectiveness of intensive LDL-C lowering, building on years of established clinical evidence. Read the press release: amgen.ly/4BU8qPs $AMGN
3
9
1,716
Why do some people develop heart disease while others don’t? Amgen research leader and AHA Population Research Prize recipient Pradeep Natarajan shares insights in a new Q&A article. amgen.ly/4iBF5Ra
1
6
18
1,867
B cells are built to protect us. But in autoimmune disease, they can become dysregulated and contribute to disease. Amgen researchers are exploring whether targeting CD19 could help address that🔬
1
10
1,152
📢 Amgen’s real-world study shows that treatment decisions to lower LDL-C impacts heart attack risk in ASCVD patients. The findings prompt a closer look at how we approach LDL-C lowering in clinical practice. 🔗 amgen.ly/47Z4v6A $AMGN
2
12
898
Amgen reports Q3 2026 earnings: amgen.ly/4iu1ik1 Amgen delivered another strong quarter, reflecting the performance our strategy was designed to achieve. Safe Harbor: amgen.ly/4iE0FER $AMGN
1
1
12
1,754
Amgen will report Q3 2026 earnings tomorrow. Details here: amgen.ly/4ivyiIB $AMGN
1
6
1,052
At AHA #ScientificSessions26, Amgen is adding to its extensive base of cardiovascular evidence, with new research exploring LDL-C management, long-term outcomes and the economic considerations of care. Explore our abstracts ⬇️
1
3
12
1,279
Every story is personal. Every voice can help bring our mission into focus. Meet people whose experiences with cancer, cardiovascular disease, rare disease and obesity have shaped their lives and perspectives. At Amgen, serving patients is our mission. We’re honored to be named to @TIME World’s Best Companies 2026 list: amgen.ly/4ipVlEY
1
7
800
Amgen will report Q3 2026 financial results on Tuesday, November 3. Details here: amgen.ly/4jM7dU0 $AMGN
1
6
1,051
Innovation has deep roots in Massachusetts, and Amgen is proud to have been part of its life sciences community for 25 years. From our research center in Cambridge, our teams continue to push the boundaries of science to advance medicines for patients around the world. Learn more about our history in Massachusetts: amgen.ly/4iqQtzr
1
2
6
970